<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01413295</url>
  </required_header>
  <id_info>
    <org_study_id>MCBRVP</org_study_id>
    <secondary_id>2009-017247-33</secondary_id>
    <secondary_id>TRA-082</secondary_id>
    <nct_id>NCT01413295</nct_id>
  </id_info>
  <brief_title>Randomized Trial With Dendritic Cells in Patients With Metastatic Colorectal Cancer</brief_title>
  <official_title>Randomized Phase II Trial in Patients With Progressive Stage IV Colorectal Cancer to Two Lines of Chemotherapy, in Order to Compare the Best Supportive Treatment Versus Treatment With Dendritic Cells Plus the Best Supportive Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundacion Clinic per a la Recerca Biomédica</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundacion Clinic per a la Recerca Biomédica</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The different alternatives used since 1996 to treat metastatic colorectal cancer (MCRC) have&#xD;
      increased the mean survival of these patients. This outstanding advance is due to the&#xD;
      extended indications for resection of hepatic metastases and to the use of new&#xD;
      chemotherapeutic drugs (fluoropyrimidine, irinotecan and oxaliplatin) and monoclonal&#xD;
      antibodies (bevacizumab, cetuximab and panitumumab). However, none of these treatments is&#xD;
      curative and the majority of patients are overwhelmed by the illness. The first line of&#xD;
      treatment for MCRC is FOLFOX and the second, irinotecan plus cetuximab for patients with wild&#xD;
      type KRAS gene (60%) with a 30% responses, and bevacizumab plus irinotecan with a 5-10% of&#xD;
      responses, in patients with mutated KRAS (40%). A treatment with autologous dendritic cells&#xD;
      (DCs) pulsed with autologous tumour antigens is proposed as a third line of therapy. A&#xD;
      randomized phase II trial would be performed, by selecting two groups of patients, one of&#xD;
      them would be treated with the best supportive treatment and the other with DCs plus the best&#xD;
      supportive treatment. The aim of the study would be to analyze the outcome after 4 months of&#xD;
      treatment. In patients treated with DCs, IFN-γ spot forming cells and proliferative responses&#xD;
      would be determined pre and post treatment in lymphocytes stimulated with autologous DCs&#xD;
      pulsed with autologous tumour antigens. Pre and post treatment serum levels of IFN-γ, TNF-α,&#xD;
      TGF-β e IL-12, would also be measured.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Actual">September 2014</completion_date>
  <primary_completion_date type="Actual">September 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>4 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>4 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">52</enrollment>
  <condition>Colorectal Neoplasms</condition>
  <arm_group>
    <arm_group_label>Dendritic Cells Vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dendritic Cells Vaccine after 2 lines of chemotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Supportive treatment</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Supportive treatment after 2 lines of chemotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dendritic Cell Vaccine</intervention_name>
    <description>Vaccination with autologous dendritic cells loaded with autologous tumor antigens</description>
    <arm_group_label>Dendritic Cells Vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Supportive treatment</intervention_name>
    <description>Supportive treatment after progression of the illness after 2 lines of chemotherapy</description>
    <arm_group_label>Supportive treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age over 18 years.&#xD;
&#xD;
          -  Capacity of understanding and signing the informed consent and to undergo the study&#xD;
             procedures.&#xD;
&#xD;
          -  Previously treated with 2 lines of chemotherapy.&#xD;
&#xD;
          -  ECOG &lt;= 2.&#xD;
&#xD;
          -  Adequate renal, hepatic and bone marrow function&#xD;
&#xD;
          -  Confirmed diagnosis of colorectal cancer with hepatic metastasis, suitable for biopsy.&#xD;
&#xD;
          -  Availability of tumor tissue, for maturing dendritic cells&#xD;
&#xD;
          -  RECIST.1 criteria&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Clinically relevant diseases or infections (HBV, HCV, HIV).&#xD;
&#xD;
          -  Pregnant or breast feeding women.&#xD;
&#xD;
          -  Immunosuppressant treatment.&#xD;
&#xD;
          -  Concurrent cancer, with the exceptions allowed by the principal investigator (PI).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ramon Vilella, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fundació Clinic Recerca Biomédica</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Clínic Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>November 2014</verification_date>
  <study_first_submitted>August 9, 2011</study_first_submitted>
  <study_first_submitted_qc>August 9, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 10, 2011</study_first_posted>
  <last_update_submitted>November 3, 2014</last_update_submitted>
  <last_update_submitted_qc>November 3, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 4, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fundacion Clinic per a la Recerca Biomédica</investigator_affiliation>
    <investigator_full_name>Ramon Vilella Puig</investigator_full_name>
    <investigator_title>Senior consultant</investigator_title>
  </responsible_party>
  <keyword>Colorectal Neoplasms</keyword>
  <keyword>Dendritic Cells</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

